uniQure N.V

Financials

Flujo de caja de las actividades operativas -134.83 M287.96 M-145.06 M-145.93 M-182.73 M-177.96 M -177.96 M Flujo de caja de las actividades de inversión -9.48 M-67.39 M-182.73 M-205.69 M162.97 M-321.62 M -321.62 M Flujo de caja de las actividades financieras 7.44 M94.86 M1.45 M362.72 M-59.49 M415.4 M 415.4 M Flujo de caja libre -144.31 M270.52 M-162.75 M-153.08 M-186.1 M-178.4 M -178.4 M

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V

Noticias

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho mejora la calificación de uniQure tras cambio en la FDA

Mizuho mejora calificación de uniQure por cambio en liderazgo de FDA

Mizuho upgrades uniQure stock rating on FDA leadership change

Avago, Lumentum among market cap stock movers on Monday

Chardan eleva el precio objetivo de uniQure tras cambio en liderazgo de la FDA

Chardan eleva precio objetivo de uniQure por cambio en liderazgo de FDA

Chardan raises uniQure stock price target on FDA leadership change